Evidence map›Paper›PMID 29499369›Full record

ReviewAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2018

The eosinophil: For better or worse, in sickness and in health.

Bruce S Bochner

Abstract readReview
In one paragraph

Review in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Are they eosinophil extracellular traps?Frontiers in immunology · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment.International journal of molecular sciences · 2023
    Review
  15. Eosinophils: A Friend or Foe in Human Health and Diseases.Kidney diseases (Basel, Switzerland) · 2023
    Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Regulation of eosinophil functions by autophagy.Seminars in immunopathology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bruce S BochnerDepartment of Medicine, Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: bruce.bochner@northwestern.edu.

Funding

Treating lung inflammation by targeting SiglecsP01HL107151 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SCHNAAR, RONALD L · 2011 to 2017
$15.4M
Using siglecs and their ligands to treat allergic diseases SALTADU19AI136443 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SCHNAAR, RONALD L · 2018 to 2022
$7.6M
Targeting Siglec-8/Siglec-F Reduce Allergic Responses In Vitro and In VivoR01AI072265 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BOCHNER, BRUCE S · 2007 to 2017
$3.9M
Targeting Siglec-8/-F to treat eosinophil and mast cell related disordersR56AI072265 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BOCHNER, BRUCE S · 2012 to 2012
$405k
NHLBI NIH HHS P01 HL107151NIAID NIH HHS R01 AI072265NIAID NIH HHS R56 AI072265NIAID NIH HHS U19 AI136443
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunity, InnateAdultAnimalsCell DifferentiationEosinophiliaEosinophilsHomeostasisHumans

Identifiers

PMID29499369
PMCPMC6087501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.